<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452568</url>
  </required_header>
  <id_info>
    <org_study_id>01-080/04</org_study_id>
    <secondary_id>(KF) 01-080/04</secondary_id>
    <nct_id>NCT01452568</nct_id>
  </id_info>
  <brief_title>Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin</brief_title>
  <official_title>Early Anticoagulation Therapy After Bioprosthetic Aortic Valve Implantation: Comparing Warfarin Versus Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal medical strategy for prevention of thromboembolic events after bioprosthetic
      aorta valve replacement (BAVR) remains controversial.

      The aim of this trial was to compare warfarin therapy (target INR of 2.0 to 3.0) against
      aspirin 150mg daily as antithrombotic therapy for the first three months after BAVR with or
      without concomitant coronary artery bypass grafting (CABG). The aim was to evaluate
      thromboembolic complications, bleeding complications and death.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemorrhagic complications</measure>
    <time_frame>3 months</time_frame>
    <description>Bleeding complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>3 months</time_frame>
    <description>TCI, stroke, Myocardial infarction (MI), Pulmonary embolism, Deep vein thrombosis (DVT) , peripheral arterial embolism, intra-cardiac thrombus formation. We expected statistically fewer thromboembolic events in the groups receiving anticoagulation with warfarin than the aspirin only groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic findings before surgery, before discharge and 3 months after implantation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Registration of surgical data and postoperative complications</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 150mg daily, starting day 1 after surgery, for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin daily dosage to International normalized ratio(INR) value between 2,0 to 3,0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>150mg/daily for three months, starting day after surgery</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>Magnyl, Acetyl salicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>marevan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with aortic valve disease where there is indication for implantation of a
             biological stented aortic valve with or without coronary bypass surgery.

          -  Age 60 years Sinus rhythm

        Exclusion Criteria:

          -  Patients planned for double valve surgery

          -  Patients with active endocarditis

          -  Patients with atrial fibrillation/flutter

          -  Patients in anticoagulation treatment of other reason.

          -  Patients with previous cerebrovascular accidents or insults.

          -  Patients with TCI

          -  Patients with hypercoagulable conditions, disseminated intervascular coagulation,
             haemophilia or any other blood coagulapathy or related condition, whereby the blood
             coagulation process is not readily controllable

          -  Patients with pacemaker

          -  Any other disease than valve disease that will considerably increase the operative
             risk and increase the probability that the patient dies within one year after the
             operation, for example because of terminal cancer

          -  Patients that is HIV-positive or have active AIDS

          -  Patients that are known drug abuser

          -  Patients in chronic haemodialysis or other types of dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter S Olsen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiothoracic Surgery, Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolaj B Lille√∏r</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiothoracic Surgery, Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sulman Rafiq</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiothoracic Surgery, Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Nikolaj B. Lilleoer</investigator_full_name>
    <investigator_title>Clinical Project Coordinator</investigator_title>
  </responsible_party>
  <keyword>Thromboembolic complications</keyword>
  <keyword>Bleeding complications</keyword>
  <keyword>Haemorrhagic complications</keyword>
  <keyword>Anticoagulant therapy</keyword>
  <keyword>Aspirin</keyword>
  <keyword>biological Aorta Valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

